Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25400457 | 0.81 | BCL2A1 (0.45) | ARPGRTRPV4 | |
| SCHEMBL30430517 | 0.81 | BCL2A1 (0.45) | ARPGRTRPV4 | |
| SCHEMBL31388140 | 0.77 | PGR (0.36) | KCNJ1KCNH2ARPGRTRPV4 | |
| SCHEMBL15819822 | 0.77 | CHRM4 (0.43) | KCNJ1KCNH2ARSCD | |
| SCHEMBL2724566 | 0.77 | KCNJ1 (0.40) | KCNJ1KCNH2ARPGR | |
| SCHEMBL27427354 | 0.75 | CYP11B1 (0.42) | ARTRPV4XDH | |
| SCHEMBL31388155 | 0.75 | ALDH1A1 (0.44) | KCNJ1KCNH2ARTBK1 | |
| SCHEMBL20510904 | 0.75 | AR (0.40) | ARTBK1 | |
| SCHEMBL30752856 | 0.74 | ACACB (0.33) | KCNJ1KCNH2ARTRPV4TBK1 | |
| SCHEMBL23099080 | 0.73 | CHRM4 (0.43) | ARTBK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025078808-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122212-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | KCNJ1 2991/4885KCNH2 3462/4885AR 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.